Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today announced plans to develop a DNA-based orthobiologics product portfolio based on research and development by Cardium's Tissue Repair Company that will initially focus on non-union bone fractu...

Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts

KEELE, England, July 27 /PRNewswire/ -- A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, ( http://www.biocomposites.com ), as an effective bone replacement material demonstrating superior bone regenerative properties...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

PRINCETON, N.J., June 29 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced today that investigators at the Fred Hutchinson Cancer Research Center, Seattle, Washington, published a paper this morning...

ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH

EXTON, Pa., April 30 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrends (R) : Bone and Mineral Metabolism in Dialysis, a syndicated publication offering comprehensive insight into the management of calcium, phosphorus and PTH in dialysis patients. The report is based on actua...

Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations

AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was presented by the company's principal investigator Dr. Denis Claude Roy during the prestigious Pre...

Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences

Produces 98% pure protein THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ -- Bone Biologics, Inc. announced today that it's contract research and development organization, Aragen Bioscience, has completed development of a recombinant cell line and initial production process for UCB-1 (NELL-1) rec...

Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert

M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company will be holding two free webinars to discuss how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) quality assuran...

Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert

M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company will be holding two free webinars to discuss how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) quality assuran...

MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases

TIRAT CARMEL, Israel, December 16 /PRNewswire/ -- InSightec Ltd. announced today that cancer patients suffering pain caused by tumors that have spread to their bones have a new online resource for information about their condition. The website, http://www.MyCancerPain.org , provides backgroun...

deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis

REYKJAVIK, Iceland, December 15 /PRNewswire-FirstCall/ -- - Findings Point to Potential Therapeutic Pathways and Provide Widening Basis for the Development of a Risk Assessment Test Scientists from deCODE genetics (Nasdaq: DCGN ) and colleagues from Australia and Denmark today rep...

New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases

TIRAT CARMEL, Israel, December 2 /PRNewswire/ -- InSightec Ltd. announced today that new publications show that Magnetic Resonance-guided Focused Ultrasound (MRgFUS) with the ExAblate(R) system has the potential to be an effective noninvasive pain-relieving treatment for tumors that have sprea...

Osteotech's Next Generation Grafting Material, MagniFuse(TM) Bone Graft, a Breakthrough in Bone Regeneration; MagniFuse(TM) Bone Graft seeks to redefine the standard of care in the U.S. bone graft substitute market estimated to be in excess of $1.2 billio

EATONTOWN, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE ), a leader in the emerging field of biologic products for regenerative healing, announced today that its next generation grafting material will be marketed under the brand name, MagniFuse(TM) Bone Graft. Robert...

Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing

MOUNTAIN VIEW, Calif., Oct. 14 /PRNewswire/ -- Based on its recent analysis of the bone healing market, Frost & Sullivan recognizes ISTO Technologies, Inc. with the 2008 North American Frost & Sullivan Award for Product Innovation for its novel InQu(R) Bone Graft Extender and Substitute scaffo...

Pioneer(R) Surgical Technology Announces Market Release of FortrOss(TM), a Next Generation Bone Void Filler

Pioneer's First In-House Biologic Product to Debut at NASS GREENVILLE, N.C. and WOBURN, Mass., Oct. 14 /PRNewswire/ -- Pioneer Surgical Technology, Inc. today announced the U.S. market release of their FortrOss bone graft substitute. The novel biologic will make its public debut at the ...

ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device

NEW AGREEMENT COVERS MARROWXPRESS(TM) IN KEY GLOBAL MARKETS RANCHO CORDOVA, Calif., Sept. 9 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL ), a leading supplier of innovative products and services that process and store adult stem cells, said today it has signed a distribut...

StemCor Systems, Inc. Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform

MENLO PARK, Calif., May 14 /PRNewswire/ -- StemCor Systems, Inc., a medical device company developing clinical systems for Enabling Regenerative Medicine(TM), announced today that it has been awarded a National Institutes of Health Phase I Small Business Innovation Research (SBIR) Grant entitl...

Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine

EATONTOWN, N.J., April 25 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE ), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Food and Drug Administration ("FDA") has cleared its 510(k) submission for the Plexur P(T...

Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease

ANN ARBOR, Mich., Feb. 4 /PRNewswire/ -- Pfizer's loss of some top talent, including Lipitor pioneer Dr. Bob Sliskovic, is the gain of two Michigan companies teaming to help speed research to fight bone diseases such as multiple myeloma, metastatic bone disease, rheumatoid arthritis and osteop...

New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Denosumab is a new drug being studied to prevent fractures in breast cancer patients receiving hormonal therapy. Results of a phase 3 clinical trial using denosumab were presented Friday evening at the San Antonio Breast Cancer Symposium by Georgiana Ellis,...

Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications

FRANKLIN LAKES, N.J., Oct. 23 /PRNewswire/ -- Collagen Matrix, Inc. announces the launch of its OssiMend(TM) Bone Graft Matrix for orthopedic and spine applications. OssiMend is an all-natural mineral-collagen composite bone graft material which, combined with autologous bone marrow, is used t...

Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures

NEW YORK, Sept. 25 /PRNewswire/ -- Small Bone Innovations, Inc. (SBi), a single-source provider of products, technology and education for the small bone and joint sector, has introduced its PRECISE SD(TM) Volar Distal Radius Locking Plate system to augment its Wrist Management portfolio. The ...

Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis

U.S. Food and Drug Administration clears new implant for marketing NEW YORK, Sept. 21 /PRNewswire/ -- Small Bone Innovations, Inc. (SBi), a single-source provider of products, technology and education for the small bone and joint sector of the orthopedic industry, announced that its Artelon...

FDA approves Bone Cares Hectorol for treatment of kidney disease

Middleton, Wis. -- Bone Care International, Inc. announced Monday the U.S. Food and Drug Administration approved a new indication and strength for Hectorol (doxercalciferol) Capsules. Hectorol, a pro-hormone vitamin D2 analog, is currently approved for the treatment of secondary hyperparathyroidi...

Plexus, Bone Care and Rockwell declare profitable first quarter

Bone Care: $1.8 million, on doubled Hectorol sales Middleton, Wis. Bone Care International, which markets a vitamin-D hormone therapy based on the work of University of Wisconsin-Madison professor Hector DeLuca, reported profits of $1.8 million for the first quarter. The company said its sale...

Massachusetts firm to buy UW spinoff Bone Care for $600 million

Madison, Wis. Massachusetts-based Genzyme Corp. said on Wednesday it has agreed to buy Bone Care International , a University of Wisconsin-Madison biotech spinoff, for $600 million in cash. Bone Care and Genzyme, a 24-year-old company with annual revenues of more than $2 billion and almost...

FTC has fast-tracked Bone Care merger

Genzyme Corporation and Middleton-based Bone Care International Inc. announced on Wednesday that the U.S. Federal Trade Commission has fast-tracked their proposed merger. Genzyme and Bone Care have signed a definitive agreement for Genzyme to acquire Bone Care in an all-cash transaction val...

Technology grants, Bone Care merger

Governor Jim Doyle today announced that three Wisconsin businesses will receive funding for technology development projects from the Department of Commerce Technology Matching Grant (TMG) and Technology Venture Fund (TVF) Programs. The three companies are Quintessence Biosciences, Inc., GWC Technol...

Genzyme acquistion of Bone Care approved, significant impact forecast

Madison, Wis. - One of Wisconsin's most prominent pharmaceutical companies has been purchased, its stock delisted and its name changed. This move will result in a continued limited presence in Wisconsin, but could also create potential opportunites for the state's life science industry, increase ...

U.S. FDA Clears GE Healthcare's New Bone Density System

MILWAUKEE The federal Food and Drug Association today approved GE Healthcare's Lunar iDXA, a new bone mineral density system designed to help doctors detect, diagnose and monitor treatment of osteoporosis, a disease characterized by low bone mass and increased risk of fracture, more accurately a...

Genzyme sues former Bone Care employees

Madison, Wis. - Saying former employees began to develop Bone Care International's trade secrets into new products, the Boston-based company that purchased Bone Care in 2005 is suing three former BCI employees and their new company, Cytochroma, Inc . Genzyme Corp . filed the suit in United ...

Electroporation of Primary Bone Marrow Cells

Contributed by Elizabeth Eustis-Turf*, Kiu-Mei Wang , and Lawrence B. Schook, Laboratory of Molecular Immunology, Department of Animal Sciences, University of Illinois, Urbana- Champaign The transfer of genes into eukaryotic cells permits t...

Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product

...tory and other assets associated with the OsseoFit bone Void Filler product line. Under the terms of the a...t will return distribution rights for the OsseoFit bone Void Filler product line to Kensey Nash, including...l have, exclusive worldwide rights to the OsseoFit bone Void Filler product line, as well as future extens...

ThermoGenesis Announces Expanded Collaboration With Celling Technologies

...diary of SpineSmith, LLC, related to the Company's bone marrow products, MXP(TM) MarrowXpress(TM) ("MXP") ...processing medical device for the concentration of bone marrow-derived stem cells at the point of care. C... bag set for concentrating stem cells derived from bone marrow. It allows clinicians to automate blood vo...

ThermoGenesis Provides Update on Fiscal 2009 Results

...es-Q System, a point of care processing device for bone marrow aspirate to concentrate stem cells, was for...ally launched in July. The Res-Q System processes bone marrow in minutes and delivers a high rate of stem...ll accelerate the market adoption of the Company's bone marrow processing technologies and increase Compan...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... glucose intolerance, neuropsychiatric disease and bone demineralization. About orBec ((R) ) ...r patients after receiving allogeneic stem cell or bone marrow transplants. Similar to acute GVHD, there ...ulti-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the United ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

...l trial were in complete hematological remission following intense chemotherapy regimens, but retained a detectable level of ALL cancer cells in their bone marrow - so called minimal residual disease (MRD). Various studies have confirmed that ALL patients with MRD following chemotherapy have a significant...

Osteotech Resumes Shipments of Bulgarian Tissue

... stated Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer. "Over the last 17 years, Grafton has been proven to outperform competitive bone grafting solutions, a position that is supported by extensive clinical studies that have demonstrated efficacy and safety. Based upon our superior pro...

Neurocrine Biosciences Reports Second Quarter 2009 Results

...ne data (first three months of placebo and active controlled treatment) to be available in the fourth quarter of this year. Petal Study (0603) bone data were presented at the Endocrine Society meeting in Washington, D.C. in June 2009 and the clinical efficacy and safety abstract from this study ha...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

... six was the impact of the elagolix 250 mg dose on bone mineral density (BMD) as measured by dual energy X...ted from extensive modeling of dose, estradiol and bone mineral density relationships. Prior to this stud... that we would start to see an increased impact on bone mineral density in a small portion of study subjec...

Sunesis Reports Financial Results for the Second Quarter 2009

...loid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred ...